von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura
- 1 December 2000
- journal article
- case report
- Published by Wiley in British Journal of Haematology
- Vol. 111 (4), 1215-1222
- https://doi.org/10.1046/j.1365-2141.2000.02503.x
Abstract
Thrombotic thrombocytopenic purpura (TTP) is characterized by microangiopathic haemolytic anaemia (MAHA), thrombocytopenia, fluctuating neurological impairment, renal dysfunction and fever. Both acquired and congenital forms are recognized. Recurrent episodes, which may be predictable (occurring every 21-28 d), are seen in congenital disease and may be treated by infusion with fresh-frozen plasma (FFP). Congenital TTP has recently been associated with deficiency of a novel von Willebrand factor (VWF)-cleaving protease. To investigate whether residual protease activity dictates clinical manifestations, we determined protease activity in three patients with congenital TTP of varying severity. Intrinsic VWF-cleaving protease activity of a range of plasma-derived products was also assessed as one patient had been successfully maintained for many years, initially using an intermediate-purity factor VIII concentrate (Kryobulin) and then cryoprecipitate. All three patients had a severe absolute deficiency of VWF-cleaving protease activity (< 3%) up to 5 months after clinical symptoms. Three relatives were also found to have a mild reduction in protease activity (25-50%). Nevertheless, the intrinsic VWF-cleaving protease activity of plasma-derived products correlated with their clinical efficacy: significant (100%) protease activity was found in FFP, cryosupernatant, solvent-detergent-treated plasma, cryoprecipitate and Kryobulin. Two clinically ineffective factor VIII products (Fahndi and Haemate P) possessed only low protease activity (6.25% and 12.5% respectively). Although this suggests that VWF-cleaving protease activity is central to the pathogenesis of congenital TTP, either small differences in protease activity below 3% or hitherto unknown factors have a profound influence on clinical phenotype. The possible use of factor VIII concentrates in the treatment of this condition also warrants further investigation.Keywords
This publication has 18 references indexed in Scilit:
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeNew England Journal of Medicine, 1998
- Increased platelet retention in familial recurrent thrombotic thrombocytopenic purpuraKidney International, 1996
- Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.Proceedings of the National Academy of Sciences, 1993
- Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remissionThe Journal of Pediatrics, 1992
- Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.Proceedings of the National Academy of Sciences, 1990
- Phast assessment of vWF:Ag multimeric distributionThrombosis Research, 1990
- Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y)British Journal of Haematology, 1990
- Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentratesBritish Journal of Haematology, 1989
- Expression and intracellular distribution of stress fibers in aortic endothelium.The Journal of cell biology, 1986
- Hazard of platelet transfusion in thrombotic thrombocytopenic purpuraJAMA, 1981